ArticleAbdominal radiology (New York)2026
Photon counting detector CTA for prostate arterial evaluation during the workup for prostate artery embolization.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate small field of view (FOV) ultra-high spatial resolution pelvic photon-counting detector prostate CT angiograms (UHR PCD CTA) for identifying prostate arterial anatomy and extraprostatic anastomoses in patients undergoing workup for prostate artery embolization (PAE).
methodsIRB-approved retrospective imaging and electronic medical record review of men who consecutively underwent UHR PCD CTA for PAE workup at our institution from 8/1/2022 to 12/1/2024. UHR PCD CTAs were evaluated by two vascular and interventional radiologists for main and accessory candidate prostatic arteries (PA/s) and anastomoses to penile, bladder, or rectal arteries. A main PA was defined as supplying the central gland and an accessory PA was defined as supplying the peripheral zone. PAs were categorized using the Carnevale classification. In patients who proceeded to PAE, digital subtraction angiograms (DSA) were retrospectively compared with UHR PCD CTA findings.
resultsUHR PCD CTA was obtained prior to PAE consultation for 50 men. We evaluated 100 pelvic sides, identifying 180 candidate PAs with a median of 3 candidate PAs per patient (mean, 3.6; range, 2-7). Overall, 56% (101/180) of candidate PAs were main and 44% (79/180) were accessory. Abridged Carnevale classifications: Type 5-21% (38/180). Eight accessory candidate PAs arose from the superior rectal artery. At least one candidate anastomosis arose from 40% (72/180) of candidate PAs. Of 95 total candidate anastomoses, 69 were extraprostatic (30 rectal, 20 bladder, 19 penile) and 26 were intraprostatic collaterals; 56% (53/95) arose from accessory and 44% (42/95) from main candidate PAs. Twenty-eight of 50 (56%) men underwent PAE, during which 72% (74/103) of available candidate PAs were selected, and prostatic supply was confirmed by DSA in 100% (74/74) of selected vessels.
conclusionSmall FOV UHR PCD CTA is useful in identifying candidate PA supply, as well as potential extraprostatic anastomoses, providing an arterial roadmap for PAE planning. Candidate PA supply was confirmed by DSA in all selected vessels among patients who proceeded to PAE.
Indexed as
Identifiers
42891702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.